
Canadian early-stage venture fund creating biotech companies from academic research

Independent European venture capital firm investing in early-stage companies developing new therapeutics

Therapeutics is the only field in which Sunstone Life Science Ventures invests. The independent European venture firm seeks out early-stage life science companies that develop new treatments for people, and it aims to help turn new science into products that improve outcomes for patients. The firm says its work also creates value for the innovators, investors and health care systems that depend on those products.
The firm's portfolio spans the full range of development stages, from preclinical drug candidates through clinical phase one, phase two and phase three trials, and on to approved medicines. Since the firm was founded in 2007, it says that it has contributed to bringing several new drugs onto the market and has supported a large number of clinical trials. That record is central to how it describes its experience with scientific and clinical decisions.
Sunstone manages its investments through a series of funds. Its fourth fund concentrates solely on therapeutics and is actively seeking new opportunities. The firm publishes an overview of companies in its portfolio, including those still active and those that have completed acquisitions or initial public offerings, so investors can see how the funds have performed over time.
The firm is supported by InnovFin Equity, which operates under the European Union's Horizon 2020 financial instruments and the European Fund for Strategic Investments created under the Investment Plan for Europe. The firm explains that the purpose of these programmes is to finance productive investment in the European Union and to widen access to capital for businesses that need it. Sunstone presents this backing as part of its commitment to European innovation.
Founders and innovators who want Sunstone to consider their project can use the contact form on the firm's website. The firm also publishes its press releases, creating an archive of the milestones and key facts in its history. For a new company, that record shows how a specialised life science investor has grown and how it has described its role in bringing new treatments to patients.
Sunstone Life Science Ventures is an independent European venture capital firm. It invests in early-stage life science companies that are developing new therapeutic treatments for people.
Innovators, investors and health care systems. The firm reports that its work since 2007 has helped bring several new medicines to market and supported many clinical trials across phases one to three.
Summary written by TrustList from the business's own published information, Nov 2026.
2 images - click to enlarge
Sunstone Life Science Ventures is ranked on 1 TrustList ranking at #3.
Every ranking orders its listings by their reviews, how complete the profile is and the Trust Score. Sunstone Life Science Ventures has no reviews yet and 3 of the 10 profile details we look for. Where no listing on a page has been reviewed, the order follows the profiles alone.
It is one of 2 here listing early stage and one of 3 here listing series.
Of the 12 here, 4 also cover science and 3 also cover series a; 8 also work in London and 7 also work in Boston.
Behind International Data Group.
As of 2026-11-16. Organic ranks only; sponsored placements are never ranks. How TrustList ranks
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about Sunstone Life Science Ventures.
Similar listings buyers compare against this one.

Canadian early-stage venture fund creating biotech companies from academic research

Venture advisory business helping early-stage companies raise capital, prepare for investors and plan exits

Seed-stage venture firm backing B2B software founders and often taking the lead investor role

Early-stage deep technology investor backing scientists and engineers in compute, energy, automation and biology

Venture fund investing in early-stage technology startups, mainly in the Pacific Northwest, from pre-seed to Series A

A European venture firm investing in seed-stage, data-driven B2B software companies

A Toronto venture firm investing in early-stage Canadian B2B technology companies

European seed-stage venture fund that backs early technology founders aiming at the US market
Everything here links back to the same verified catalogue. Pick your next stop.